On August 16, 2026, Mesoblast Limited, a leading global provider of allogeneic cellular medicines for inflammatory disorders, disclosed the completion of patient treatment in the MSB-DR004 Phase 3 trial. This trial focused on rexlemestrocel-L for chronic low back pain related to degenerative disc disease. The milestone was marked by treating 350 patients who were randomly assigned to receive either rexlemestrocel-L intra-discal injections or sham injections. Originally planned for 300 patients, the trial's capacity expanded due to high demand from investigators, resulting in an additional 50 patients being enrolled. Mesoblast Limited's stocks are listed on Nasdaq under MESO and ASX under MSB.